MiMBa Pregnancy Registry
Key facts
- Who runs it
- Liverpool School of Tropical Medicine
- Where
- Burkina Faso and Kenya2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 15,391 people enrolled
- Started
- 22 Feb 2021
- Ended
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Record updated
- 14 August 2026
Who can take part
- Age
- 15 years to 49 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Pregnant or women of childbearing age (15-49 years); Resident within the defined catchment area. Residency status will be defined as having resided in the area for at least four months; Willingness to attend antenatal care and deliver in the study area; Willingness to give informed consent (and assent for non-pregnant WOCBAs under 18 years of age)
Who cannot take part
- Refusal to participate or be followed up to the end of pregnancy. • Any medical, psychiatric, or social condition that would interfere with the ability to provide an accurate medical or drug history or the volunteer's ability to give informed consent (e.g. mentally disabled patients)
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The MiMBa (Malaria in Mothers and Babies) Pregnancy Registry aims to generate robust evidence on the safety of a range of antimalarials when used in pregnancy, particularly in the first trimester. This will be a multi-country observational study and will be deployed in several field sites in Africa.
The 2 groups in the trial
- Pregnant Women exposed to antimalarials during pregnancy
Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
- Pregnant Women unexposed to antimalarials during pregnancy
Pregnant women will be followed up prospectively. In certain sites, women of childbearing age (15-49 years) will be enrolled prior to pregnancy to ensure early pregnancy detection. Pregnancy and infant outcomes will be assessed systematically and recorded.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pregnancy Registry to Assess the Safety of Antimalarial Use in Pregnancy
- Record updated
- 14 August 2026